
Novo Nordisk
NONOF | OTC
$37.01
-$0.37 (-0.99%)
At close: Oct 2, 2026, 3:58 PM ET
Novo Nordisk Company Profile
Company profile explainedCompany Profile
Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.
Key Executives
| Name | Position |
|---|---|
| Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board |
| Maziar Mike Doustdar | President, Chief Executive Officer & Member of the Management Board |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board |
| Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board |
| Hong Chow | Executive Vice President of Product & Portfolio Strategy and Member of Management Board |
| Jamey Millar | Executive Vice President of US Operations & Member of Management Board |
| John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
| Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |
Novo Nordisk

| Country | Denmark |
| IPO Date | May 7, 2010 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 68,794 |
| CEO | Maziar Mike Doustdar |
Stock Details
| Ticker Symbol | NONOF |
| Exchange | OTC |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000353278 |
| CUSIP Number | n/a |
| ISIN Number | DK0062498333 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove NONOF